| Literature DB >> 28388876 |
Biju Joseph Ampattu1, Laura Hagmann1, Chunguang Liang2, Marcus Dittrich2,3, Andreas Schlüter4, Jochen Blom5, Elizaveta Krol6, Alexander Goesmann5, Anke Becker6, Thomas Dandekar2, Tobias Müller2, Christoph Schoen7.
Abstract
BACKGROUND: Commensal bacteria like Neisseria meningitidis sometimes cause serious disease. However, genomic comparison of hyperinvasive and apathogenic lineages did not reveal unambiguous hints towards indispensable virulence factors. Here, in a systems biological approach we compared gene expression of the invasive strain MC58 and the carriage strain α522 under different ex vivo conditions mimicking commensal and virulence compartments to assess the strain-specific impact of gene regulation on meningococcal virulence.Entities:
Keywords: Cryptic genetic variation; MITE; Metabolism; Neisseria meningitidis; Regulatory evolution; RelA; Stringent response; Systems biology; Virulence
Mesh:
Substances:
Year: 2017 PMID: 28388876 PMCID: PMC5383966 DOI: 10.1186/s12864-017-3616-7
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Strains used for ex vivo transcriptome comparisons
| α522 | MC58 | |
|---|---|---|
| Genome characteristics | ||
| GenBank accession number | FR845693 to FR845718 | AE002098 |
| No. of contigs in final assembly | 21 | 1 |
| Average single base coverage | 79-fold | 8.4-fold |
| Genome size (bp) | ≥2,074,170 | 2,272,360 |
| GC content (%) | 51.78% | 51.53% |
| Predicted number of coding sequences | ≥1985 | 2063 |
| Reference | This work | Tettelin et al. (2000) [ |
| Molecular epidemiology | ||
| Source | Carrier | Patient |
| Country and year of isolation | Germany 2000 | United Kingdom 1983 |
| Sequence type | ST-35 | ST-74 |
| Clonal complex (CC) | ST-35 | ST-32 |
| Phylogenetic clade (PC) (a) | PC32/269 | PC32/269 |
| Frequency of CC in carriers(b) | 5.47% | 4.99% |
| Disease/carriage ratio(c) | 0.5 | 3.5 |
| Reference | Claus et al. (2005) [ | McGuiness et al. (1991) [ |
| Phenotypic characterization | ||
| Serum resistance (%)(d) | 117.7 ± 23.8 | 116.3 ± 15.7 |
| Adhesion to epithelial cells(e) | ||
| FaDu cells (%) | 10.7 ± 7.4 | 14.5 ± 8.5 |
| Detroit562 cells (%) | 8.9 ± 1.8 | 17.1 ± 5.3 |
| Invasion of epithelial cells(e) | ||
| FaDu cells (%) | 0.0008 ± 0.0001 | 0.0020 ± 0.0011 |
| Detroit562 cells (%) | 0.0011 ± 0.0004 | 0.0016 ± 0.0007 |
| In vitro logarithmic growth rates(f) | ||
| Rich medium (PPM+) (1/h) | 0.46 ± 0.01 | 0.47 ± 0.01 |
| Minimal medium (MMM) (1/h) | 0.06 ± 0.01 | 0.52 ± 0.02 |
| Ex vivo growth rates(g) | ||
| Saliva (1/min) | −0.041 ± 0.003 | −0.043 ± 0.003 |
| Blood (1/min) | 0.027 ± 0.004 | 0.023 ± 0.002 |
| CSF (1/min) | 0.010 ± 0.002 | 0.018 ± 0.003 |
(a) According to ref. [27, 28]
(b) According to ref. [100]
(c) According to ref. [2]
(d) Ratio in percent of viable bacteria after incubation for 30 min in the presence of 10% human serum and viable bacteria incubated without serum. Given are the average and standard deviation from four independent experiments with pooled human serum
(e) Ratio in percent of adherent and invasive bacteria, respectively, to total bacteria. Given are the average and standard deviation from at least four independent experiments
(f) Given are the mean and standard deviation of the logarithmic growth rate k according to log(OD (t)/OD (0)) = kt for t ∈ [1 h, 4 h] as depicted in Fig. 5 using linear regression (R 2 = 0.96 ± 0.07, p = 0.013 ± 0.026)
(g) Given are the mean and standard deviation of the growth rate k according to log(N(t)/N(0)) = kt for t ∈ [0 min, 120 min] as depicted in Fig. 5 using linear regression (R 2 ex vivo = 0.95 ± 0.05, p ex vivo = 0.018 ± 0.016)
Fig. 5Growth phenotypes of N. meningitidis MC58 and α522 wild-type and mutant strains. a In vitro growth phenotypes. Growth as quantified by the optical density (OD600nm) is given on the ordinate and the time in hours on the abscissa. b Ex vivo growth phenotypes. The number of colony forming units for each time point (N(t)) relative to the initial number (N(0)) is given on the ordinate and the time in minutes on the abscissa. For each strain and condition the respective growth curves are coded as indicated in the insert in each panel, and the genotypes of the respective strains compared are shown along with the corresponding growth curves. In each experiment rich medium (PPM+) was used as growth control. The arrow at the top of panel b indicates the time when total RNA was extracted for microarray analysis
Fig. 1Genes significantly differently expressed and/or regulated in cross-condition and/or cross-strain comparisons. a Venn diagram comparing sets of genes in strain MC58 differently expressed between conditions as indicated. The total number of genes compared was 1987. b Venn diagrams comparing sets of genes differently expressed between strains as indicated with each diagram. The total number of genes compared in each panel was 1450. c Heatmap depicting cross-condition and cross-strain gene expression differences and hierarchical clustering of significantly differently expressed genes. Average linkage clustering based on the Spearman rank correlation of all 828 genes significantly differently expressed and/or regulated in at least one cross-condition and/or cross-strain comparison (FDR < 0.05). Grey lines correspond to genes that were absent in the α522 genome sequence and therefore excluded from the cross-strain comparisons
Significantly enriched COG functional categories in cross-condition and cross-strain comparisons
| Non-directional(a) | Directional(b) | |||
|---|---|---|---|---|
| COG functional category | OR(c) | FDR(d) | OR(e) | FDR(d) |
| MC58 cross-condition comparisons | ||||
| Saliva ↔ Blood | ||||
| Nucleotide transport and metabolism (COG F) | 2.66 | 0.044 | n.s. | n.s. |
| Energy metabolism and conversion (COG C) | n.s. | n.s. | 0.18 | 0.024 |
| Cell wall/membrane/envelope biogenesis (COG M) | n.s. | n.s. | 0.31 | 0.020 |
| Posttranslational modification, protein turnover, chaperones (COG O) | n.s. | n.s. | 0.13 | 0.023 |
| Not in COG | n.s. | n.s. | 6.53 | <0.001 |
| Blood ↔ CSF | ||||
| Not in COG | n.s. | n.s. | 0.06 | <0.001 |
| MC58 versus α522 cross-strain comparisons | ||||
| Blood | ||||
| Energy metabolism and conversion (COG C) | 2.25 | 0.008 | 11.6 | <0.001 |
| Cell wall/membrane/envelope biogenesis (COG M) | n.s. | n.s. | 0.19 | <0.001 |
| Saliva ↔ Blood | ||||
| Energy metabolism and conversion (COG C) | 2.99 | <0.001 | >5.33 | <0.001 |
| Translation, ribosomal structure and biogenesis (COG J) | n.s. | n.s. | 0.04 | <0.001 |
| Cell wall/membrane/envelope biogenesis (COG M) | n.s. | n.s. | 0.09 | 0.003 |
| Blood ↔ CSF | ||||
| Energy metabolism and conversion (COG C) | 3.27 | <0.001 | n.s. | n.s. |
(a) Comparison of differently versus non-differently expressed genes to identify COG categories that are affected by differential expression in general
(b) Comparison of differentially expressed genes to identify COG categories that are significantly affected by regulation in a distinct direction (gene expression asymmetry)
(c) Odds ratios based on Fisher’s exact test. Values greater than 1 indicate that significantly differentially expressed genes are enriched for genes from the corresponding COG functional class
(d) False discovery rate based on p-values from Fisher’s exact test and the Benjamini-Hochberg multiple testing correction with a significance cut-off of FDR < 0.05
(e) For cross-condition comparisons, values greater than 1 indicate that genes highly expressed in blood were enriched for the respective COG category. In cross-strain comparisons, values greater than 1 indicate that the respective COG category is significantly highly expressed or upregulated in strain MC58
Fig. 2Gene set enrichment analysis of differently expressed genes. a Non-directional comparison of significantly differently expressed gene sets according to the COG functional classification scheme for cross-condition and cross-strain comparisons, respectively, indicating significantly overrepresented functional categories among the significantly differently expressed genes. b Directional comparison of significantly differently expressed gene sets according to the COG functional classification scheme for cross-condition and cross-strain comparisons, indicating significant gene expression asymmetries. In both panels, the heat map depicts significantly enriched COG functional categories in red coloring. The kind of comparison (cross-condition for strain MC58 and cross-strain for each condition) is indicated for each column of the heat maps, and the corresponding FDRs are color coded and given in the respective inserts. The associated tree is based on average linkage clustering of the functional categories using the Spearman rank correlation coefficient
Differentially expressed genes coding for putative virulence genes and genes involved in meningococcal host interactions(a)
| Locus | Gene | Product Name | Log2-fold expression level differences | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| in MC58 comparing | between MC58 and α522 in | |||||||||
| Saliva vs. Blood(b) | Blood vs. CSF(c) | PPM+(d) | Saliva(d) | Blood(d) | CSF(d) | Blood vs. Saliva(e) | CSF vs. Blood(f) | |||
| Transcription | ||||||||||
| NMB0594 |
| PhoQ-family sensor histidine kinase | n.s.(g) | n.s. | n.s. | n.s. | −2.50 | n.s. | −2.00 | 2.51 |
| NMB0595 |
| PhoP-family response regulator | −0.89 | 1.09 | n.s. | n.s. | 1.64 | n.s. | −2.00 | 2.51 |
| Capsule synthesis | ||||||||||
| NMB0068 |
| Capsule biosynthesis protein SiaC | 2.07 | −1.45 | n.s. | n.s. | −1.67 | −1.72 | n.s. | n.s. |
| NMB0069 |
| Capsule biosynthesis protein SiaB | 2.33 | n.s. | −1.66 | −1.58 | −2.73 | −1.93 | n.s. | n.s. |
| NMB0070 |
| Capsule biosynthesis protein SiaA | 2.85 | n.s. | −1.63 | −2.94 | −2.85 | −1.93 | n.s. | n.s. |
| NMB0072 |
| Capsule export protein CtrB | 2.28 | n.s. | n.s. | n.s. | n.s. | −1.36 | n.s. | n.s. |
| NMB0083 |
| Capsule modification protein | n.s. | n.s. | n.s. | n.s. | −1.66 | n.s. | n.s. | n.s. |
| LOS synthesis | ||||||||||
| NMB0014 |
| 3-Deoxy-D-manno-octulosonic-acid transferase | n.s. | n.s. | n.s. | n.s. | −2.83 | n.s. | −2.84 | 2.58 |
| NMB0017 |
| UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase | n.s. | n.s. | n.s. | n.s. | −1.24 | n.s. | n.s. | n.s. |
| NMB0178 |
| UDP-N-acetylglucosamine acyltransferase | n.s. | n.s. | n.s. | n.s. | 1.54 | n.s. | n.s. | n.s. |
| NMB0180 |
| UDP-3-O-[3-hydroxymyristoyl] glucosamine N-acyltransferase | −1.40 | n.s. | n.d.(h) | n.d. | n.d. | n.d. | n.d. | n.d. |
| NMB0199 |
| Lipid-A-disaccharide synthase | n.s. | n.s. | n.s. | n.s. | −2.92 | n.s. | n.s. | n.s. |
| NMB1704 |
| Beta-1,4-glucosyltransferase | n.s. | n.s. | n.s. | n.s. | −2.82 | n.s. | n.s. | n.s. |
| NMB1928 |
| Lacto-N-neotetraose biosynthesis glycosyl transferase LgtB | −1.27 | n.s. | n.s. | n.s. | n.s. | n.s. | −1.56 | n.s. |
| NMB2156 |
| Lipopolysaccharide heptosyltransferase I | 2.20 | n.s. | n.s. | n.s. | −1.03 | n.s. | n.s. | n.s. |
| Pilus synthesis | ||||||||||
| NMB0052 |
| Twitching motility protein PilT | n.s. | n.s. | −0.93 | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0329 |
| Type IV pilus assembly protein | −0.80 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0333 |
| Pilus assembly protein PilG | n.s. | 0.98 | n.s. | n.s. | 2.86 | n.s. | 2.62 | −2.32 |
| NMB0768 |
| Twitching motility protein PilT | 1.36 | n.s. | n.s. | n.s. | 2.08 | n.s. | 2.18 | −1.74 |
| NMB1811 |
| PilP protein | n.s. | −0.86 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB1820 |
| Pilin glycosylation protein PglB | −1.69 | n.s. | n.s. | n.s. | −1.46 | n.s. | n.s. | n.s. |
| NMB1821 |
| Pilin glycosylation protein PglC | −1.73 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| Efflux pumps | ||||||||||
| NMB0318 |
| Fatty acid efflux system protein | −4.60 | n.s. | n.s. | n.s. | −1.41 | n.s. | −2.28 | n.s. |
| NMB1714 |
| Multidrug efflux pump protein MtrE | −4.47 | 2.46 | n.s. | n.s. | −2.85 | n.s. | n.s. | n.s. |
| NMB1715 |
| Multiple transferable resistance system protein MtrD | −3.35 | 2.06 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| Adhesins and OMPs | ||||||||||
| NMB0181 |
| Putative outer membrane protein OmpH | −1.05 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0182 |
| Outer membrane protein OMP85 | −0.98 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0382 |
| Outer membrane protein class 4 | n.s. | n.s. | n.s. | −0.87 | n.s. | n.s. | n.s. | n.s. |
| NMB0497 |
| Hemagglutinin/hemolysin-related protein | 3.45 | n.s. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| NMB0663 |
| Outer membrane protein NspA | 1.46 | −1.19 | n.s. | n.s. | 4.23 | n.s. | 3.92 | −3.63 |
| NMB1053 |
| Class 5 outer membrane protein OpcA | n.s. | n.s. | 7.39 | 6.47 | 6.65 | 6.71 | n.s. | n.s. |
| NMB1214 |
| Hemagglutinin/hemolysin-related protein | n.s. | −2.00 | n.s. | n.s. | 3.62 | n.s. | 3.60 | −3.74 |
| NMB1946 |
| Outer membrane lipoprotein | −0.92 | n.s. | n.s. | 0.78 | 1.53 | 0.78 | n.s. | n.s. |
| NMB1969 |
| Serine type autotransporter | n.s. | n.s. | 0.88 | 1.64 | 1.05 | 1.08 | n.s. | n.s. |
| Iron homeostatsis | ||||||||||
| NMB0460 |
| Transferrin-binding protein B | 1.84 | n.s. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| NMB0584 |
| FrpC operon protein | n.s. | n.s. | n.s. | n.s. | 1.20 | n.s. | n.s. | n.s. |
| NMB0585 |
| Putative iron-regulated protein FrpA | 1.09 | n.s. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| NMB1206 |
| Bacterioferritin B | n.s. | n.s. | n.s. | n.s. | 2.18 | n.s. | 1.56 | n.s. |
| NMB1207 |
| Bacterioferritin A | n.s. | n.s. | n.s. | n.s. | 2.16 | n.s. | 1.58 | −1.39 |
| NMB1540 |
| Lactoferrin-binding protein A | 2.02 | n.s. | n.s. | −1.56 | n.s. | n.s. | 2.16 | n.s. |
| Stress response | ||||||||||
| NMB0278 |
| Thiol:disulfide interchange protein DsbA | n.s. | n.s. | n.s. | n.s. | 2.12 | n.s. | 1.94 | −1.74 |
| NMB0294 |
| Thiol:disulfide interchange protein DsbA | n.s. | 1.38 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0587 |
| ABC-type Mn2+/Zn2+ transporter, permease | n.s. | n.s. | n.s. | n.s. | −3.06 | n.s. | −1.94 | 2.49 |
| NMB0588 |
| ABC-type Mn2+/Zn2+ transporer, ATPase | n.s. | n.s. | n.s. | −1.53 | −2.26 | n.s. | n.s. | n.s. |
| NMB1398 |
| Superoxide dismutase | n.s. | n.s. | n.s. | n.s. | 1.99 | n.s. | 2.28 | −1.65 |
| Others | ||||||||||
| NMB0035 |
| P47 lipoprotein | n.s. | n.s. | −1.15 | n.s. | n.s. | n.s. | 2.03 | n.s. |
| NMB0065 |
| Hypothetical protein NMB0065 | 4.24 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0179 |
| (3R)-Hydroxymyristoyl-ACP dehydratase | −1.21 | n.s. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| NMB0543 |
| L-Lactate permease | n.s. | n.s. | n.s. | n.s. | 1.04 | n.s. | 1.39 | n.s. |
| NMB0700 |
| IgA-specific serine endopeptidase | n.s. | −1.57 | n.d. | n.d. | n.d. | n.d. | n.s. | n.s. |
| NMB0718 |
| ferrochelatase | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | −1.37 | n.s. |
| NMB0757 |
| phosphoribosylaminoimidazole-succinocarboxamide synthase | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | 1.71 | n.s. |
| NMB0790 |
| Phosphoglucomutase | n.s. | n.s. | 1.43 | n.s. | 2.52 | 1.76 | 2.52 | n.s. |
| NMB0825 |
| Putative ADP-heptose synthase | −1.11 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB0995 |
| Macrophage infectivity potentiator-related protein | 2.52 | n.s. | n.s. | n.s. | n.s. | 3.28 | n.s. | 3.06 |
| NMB1332 |
| Carboxy-terminal peptidase | −0.90 | n.s. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| NMB1343 |
| Hypothetical protein NMB1343 | 1.29 | n.s. | n.s. | n.s. | 1.50 | n.s. | 2.01 | −1.85 |
| NMB1436 |
| Hypothetical protein | n.s. | n.s. | n.s. | n.s. | 2.60 | n.s. | 2.81 | −2.18 |
| NMB1437 |
| Hypothetical protein | −0.87 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB1438 |
| Hypothetical protein | −1.26 | n.s. | n.s. | n.s. | 1.58 | n.s. | 1.87 | n.s. |
| NMB1622 |
| Nitric oxide reductase | n.s. | n.s. | n.s. | n.s. | 5.85 | n.s. | 5.40 | n.s. |
| NMB1623 |
| Copper-containing nitrite reductase | n.s. | n.s. | n.s. | n.s. | 5.67 | n.s. | 5.55 | −4.60 |
| NMB1829 |
| TonB-dependent receptor | −5.50 | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB1840 |
| Conserved membrane protein | n.s. | n.s. | n.s. | n.s. | 1.78 | n.s. | 3.04 | −2.20 |
| NMB1898 |
| Lipoprotein | −1.11 | 1.11 | −1.17 | n.s. | n.s. | n.s. | n.s. | n.s. |
| NMB1961 |
| VacJ-related protein | n.s. | n.s. | n.s. | n.s. | −2.03 | n.s. | −1.47 | 1.47 |
(a) Virulence-associated genes were compiled from table 2 in ref. [21], table 1 in ref. [38], table 11.2 in ref. [39], and Additional file 1 from ref. [40] (see also Additional file 2 : S1). Only those genes are included in the transcriptome comparisons that showed significant expression differences in at least one type of comparison
(b) Positive values indicate that the gene is expressed at higher levels in blood than in saliva
(c) Positive values indicate that the gene is expressed at higher levels in CSF than in blood
(d) Positive values indicate that the gene is expressed at higher levels in strain MC58 than in α522
(e) Positive values indicate that the gene expression difference between saliva and blood is greater in strain MC58 than it is in α522
(f) Positive values indicate that the gene expression difference between blood and CSF is greater in strain MC58 than it is in α522
(g) n. s., not significant
(h) n. d., no data due to missing α522 genome sequence data
Fig. 3Analysis of gene expression data based on protein-protein interaction networks. a Integrative network analysis of differently expressed genes between strain MC58 and α522 in human whole blood based on the STRING protein-protein interaction network for strain MC58 (FDR < 10−9). A subnetwork that consists predominantly (30/35) of genes that were expressed at higher levels in MC58 than in α522 and that code for metabolic genes and in particular for genes involved in energy production and conversion (85%) is shaded in orange. The remaining part of the network comprising 128 protein-coding genes is shaded in light blue. b Integrative network analysis of gene regulation differences between both strains upon transition from saliva to blood (FDR < 10−7). The two modules consisting predominantly of genes either upregulated in α522 (15/25) or MC58 (47/59) upon transition from saliva to blood are shaded in green and orange, respectively. Only 21% of the genes in the left subnetwork consisting mainly of genes that were upregulated in α522 code for proteins involved in (energy) metabolism compared to over 66% of the genes that were upregulated in MC58 upon transition from saliva to blood. For each gene, the respective expression differences between conditions and strains, respectively, are color coded and indicated in each panel. White boxes indicate genes that were not differently expressed but are part of a subnetwork as identified by the integrative network analysis. Pie charts next to the sub-networks in each panel show the distribution of proteins in the respective subnetwork over the different COG functional classes
Fig. 4Analysis of gene expression data based on a metabolic model for strain MC58. a Comparison of elementary mode activities in MC58 and α522. The histogram depicts differences in the elementary mode activities (ordinate) for each of the elementary metabolic modes (abscissa) as defined in the Additional file 3: S2 for strain MC58 (red) and α522 (blue) based on gene expression data in human blood. b Inferred differences in metabolic fluxes between strain MC58 and strain α522 in blood based on a metabolic model for strain MC58. Internal metabolites which are considered to have balanced concentrations are given by dark green spheres, external metabolites which are allowed to accumulate or to be consumed by green cones, and reactions together with their corresponding numbers as light green boxes. The reactions for all reaction numbers are given in the Additional file 3: S2. Arrows connect reaction with metabolites. Red coloring indicates higher fluxes in MC58 compared to strain α522, whereas blue colouring indicates that the flux is slightly enhanced in α522. Asterisks along with pink colouring indicate that the reaction has an opposite direction in both strains
Inferred reaction activity differences between MC58 and α522 in human blood based on gene cross-strain expression differences
| Reaction | Chemical Equation | Enzyme(s) | Ratio(a) |
|---|---|---|---|
| R030 | AKG + NADPH + NH3 = GLU + NADP | Glutamate dehydrogenase | −14.85 |
| R031 | ATP + GLU + NH3 = ADP + GLN | Glutamine synthetase | −3.03 |
| R047 | AcCoA + H2S + SER = ACE + CYS + CoA | Serine acetyltransferase + cysteine synthase | −2.32 |
| R001 | AcCoA + OXA = CIT + CoA | Citrate-synthase | 13.86 |
| R002 | NADP + CIT = CO2 + NADPH + AKG | Aconitase | 13.86 |
| R015 | CO2 + PEP = OXA | Phosphoenolpyruvate carboxylase | 11.90 |
| R052 | 3PG + GLU + NAD = AKG + NADH + SER | Serine synthesis: 3PG dehydrogenase + pserine aminotransferase + pserine phosphatase (SerA+ SerB + SerC) | 7.63 |
| R053 | SER = GLY | Serine hydroxymethyltransferase | 7.45 |
| R056 | AcCoA + GLU + IVA + NAD = AKG + CO2 + CoA + LEU + NADH | Leucine synthesis: isopropylmatate synthase + isopropylmalate dehydratase + isopropylmalate dehydrogenase + aminotransferase (LeuA + LeuB + LeuC + LeuD) | 6.78 |
| R061 | CHOR = PRE | Chorismate mutase | 12.58 |
| R062 | GLU + PRE = AKG + CO2 + PHE | Aminotransferase + phenyalanine synthesis | 12.58 |
| R063 | GLU + NAD + PRE = AKG + CO2 + NADH + TYR | Aminotransferase + tyrosine synthesis | 12.58 |
| R117 | ACA + NADH = ETH + NAD | Alcohol dehydrogenase | 14.74 |
| R118 | ACE + NADH = ACA + NAD | Aldehyde dehydrogenase | 14.74 |
| R155 | ACE = ACE_ext + H_ext | Acetate transporter | 11.50 |
| R049 | O2 + THS = 2 SO3 | Thiosulfate reductase | 0.61 |
| R050 | 3 NADPH + SO3 = H2S + 3 NADP | Sulfite reductase | 0.71 |
| R132 | H2S = HS−_ext + H_ext | Sulfur transporter | 0.45 |
(a) Ratio of the reaction activity in MC58 divided by the reaction activity in α522. A ratio larger than one indicates that the reaction has a higher activity in MC58, and a negative ratio that the reaction occurs in opposite directions both strains
Differentially expressed genes involved in transcription and signal transduction (COG categories K and T)
| Locus | Gene | Product | Log2-fold expression level differences | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| in MC58 comparing | between MC58 and α522 in | |||||||||
| Saliva vs. Blood(a) | Blood vs. CSF(b) | PPM+(c) | Saliva(c) | Blood(c) | CSF(c) | Saliva vs. Blood(a) | Blood vs. CSF (b) | |||
| Phospho transfer and signal transduction systems | ||||||||||
| NMB0594 |
| Sensor kinase | n. s.(d) | n. s. | n. s. | n. s. | −2.50 | n. s. | −2.00 | 2.51 |
| NMB0595 |
| Response regulator | −0.89 | 1.09 | n. s | n. s. | 1.64 | n. s. | 1.30 | n. s. |
| NMB0736 |
| Nitrogen regulator IIA | 1.41 | n. s. | n. a.(e) | n. a. | n. a. | n. a. | n. a. | n. a. |
| NMB1267 |
| Tyrosine-phosphatase | −1.50 | n. s. | n. s. | n. s. | −1.85 | n. s. | n. s. | n. s. |
| NMB1250 |
| Response regulator | −1.57 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1792 |
| Sensor histidine kinase | 4.46 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| HTH-type transcriptional regulators | ||||||||||
| NMB0380 |
| Crp/FNR family regulator | 1.38 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB0398 |
| ArsR-family regulator | 2.34 | n. s. | 1.86 | n. s. | 2.09 | n. s. | n. s. | n. s. |
| NMB0573 |
| AsnC-family regulator | 1.69 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB0810 |
| TetR family regulator | 1.42 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB0910 |
| Putative phage regulator | 1.73 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1007 |
| Putative phage regulator | 2.29 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1009 |
| Putative phage regulator | 3.19 | −1.46 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1378 |
| Iron-sulphur cluster-assembly repressor IscR | −1.67 | n. s. | n. s. | n. s. | −1.82 | n. s. | −2.07 | 1.77 |
| NMB1563 |
| GntR-family regulator | n. s. | 1.09 | n. d.(f) | n. d. | n. d. | n. d. | n. a. | n. a. |
| NMB1711 |
| FadR-family regulator | −3.35 | 1.52 | n. s. | n. s. | n. s. | n. s. | n. a. | n. a. |
| NMB1891 |
| Putative phage regulator | −1.07 | n. s. | n. s. | n. s. | −1.37 | n. s. | −2.29 | 1.46 |
| NMB2075 |
| Bifunctional biotin-[acetyl-CoA-carboxylase] ligase/pantothenate kinase | n. s. | n. s. | n. s. | n. s. | −1.34 | n. s. | −1.87 | n. s. |
| Alternative sigma factors | ||||||||||
| NMB0712 |
| Alternative sigma factor σH | −2.56 | 1.22 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB2144 |
| Alternative sigma factor σE | n. s. | n. s. | n. s. | −1.48 | −3.25 | n. s. | n. s. | 2.65 |
| Others factors involved in gene regulation and stress response | ||||||||||
| NMB0009 |
| BolA family protein | 1.66 | −0.99 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB0056 |
| DnaK suppressor protein | n. s. | n. s. | n. s. | n. s. | −1.44 | n. s. | n. s. | n. s. |
| NMB0126 |
| Antitermination factor NusG | n. s. | −0.99 | n. s. | n. s. | 1.01 | n. s. | n. s. | −1.55 |
| NMB0282 |
| Exoribonuclease II/R | n. s. | n. s. | n. s. | n. s. | −3.57 | n. s. | n. s. | n. s. |
| NMB0577 |
| Truncated NosR-like protein | −2.24 | 1.68 | n. s. | n. s. | n. s. | n. s. | n. a. | n. a. |
| NMB0617 |
| Termination factor Rho | −1.57 | n. s. | n. s. | n. s. | n. s. | n. s. | n. a. | n. a. |
| NMB0686 |
| Endoribonuclease III | −1.68 | n. s. | n. s. | n. s. | n. s. | n. s. | n. a. | n. a. |
| NMB0787 |
| Periplasmic amino acid-binding protein | 1.93 | −1.47 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1336 |
| Hypothetical protein | n. s. | 1.33 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1368 |
| Putative RNA helicase | n. s. | n. s. | n. s. | 1.27 | n. s. | n. s. | −2.27 | n. s. |
| NMB1430 |
| Elongation factor GreA | 1.18 | n. s. | n. s. | n. s. | −1.65 | n. s. | n. s. | n. s. |
| NMB1493 |
| Carbon starvation protein A | n. s. | n. s. | n. s. | n. s. | 3.42 | n. s. | 4.10 | −3.44 |
| NMB1500 |
| Hypothetical protein | n. s. | −0.81 | n. s. | n. s. | 1.83 | n. s. | 2.18 | −1.71 |
| NMB1642 |
| Termination factor NusA | n. s. | n. s. | n. s. | n. s. | −2.21 | n. s. | −2.17 | 1.66 |
| NMB1653 |
| Hypothetical protein | 1.29 | −1.22 | n. s. | n. s. | 2.17 | n. s. | n. s. | −2.25 |
| NMB1660 |
| RNAP omega chain | 1.59 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1735 |
| GTP pyrophosphokinase | n. s. | n. s. | n. s. | n. s. | 1.82 | n. s. | n. s. | n. s. |
| NMB1886 |
| Hypothetical protein | −1.23 | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. | n. s. |
| NMB1944 |
| ParB family protein | 1.07 | n. s. | n. s. | n. s. | n. s. | n. s. | n. a. | n. a. |
| NMB1981 |
| S-ribosylhomocysteinase | −1.14 | n. s. | n. a. | n. a. | n. a. | n. a. | n. a. | n. a. |
| NMB2037 | Hypothetical protein | 1.22 | n. s. | n. s. | n. s. | 1.48 | n. s. | 2.40 | n. s. | |
(a) Positive values indicate that the gene is highly expressed in blood
(b) Positive values indicate that the gene is highly expressed in CSF
(c) Positive values indicate that the gene is highly expressed in strain MC58
(d) n. s. not significant
(e) n. a. not applicable due to high sequence divergence between bot hhomologs
(f) n. d. no data due to missing α522 genome sequence data
Fig. 6GC content variation in potential promoter regions based on the MC58 genome sequence. a Scatter plot of the GC content variation averaged over a 5-bp sliding window within 100 bp upstream regions for genes highly expressed in MC58 (red and yellow lines) or α522 (light and dark blue lines) in human blood. The black line gives the GC content of the respective upstream regions for genes not differently expressed. Regulatory regions are indicated at the top of the panel based on the average length of 5’-untranslated regions in N. gonorrhoeae [75]. The insert gives the number of genes in each gene set. b Box-and-whiskers plot depicting differences in the mean GC content of the putative discriminator (left) and Hfq-binding regions (right) between genes highly expressed in MC58 (red) or α522 (blue) in human blood as depicted in panel (a). The line within each box gives the median and the upper and lower margins the upper and the lower quartile, respectively. The whiskers denote the highest and the lowest values, respectively, and the open circles outliers. *: p < 0.05, **: p < 0.01 (Wilcoxon test)
Fig. 7Genomic distribution of ATRs and the relA locus in N. meningitidis. a The intergenic region between grxB and relA. The integration site of a copy of an ATR repeat element upstream of relA (ATR) in strain α522 is indicated with respect to the MC58 locus. The transcriptional start sites as determined by 5’-RACE in both strains are indicated along with the deduced −35 and −10 boxes and the computationally predicted promoter regions using PPP [117]. DR: direct repeat. b Alignment of both the MC58 (upper lane) and α522 (lower lane) genomes as visualized with the Artemis comparison tool based on a BLASTN comparison. The linearized MC58 and α522 genomes are shown in the upper and lower panel as gray bars, and regions syntenic in both genomes are connected via red and inverted regions via blue lines, respectively. The location of ATRs is indicated by small arrows in each genome, and the relA region is highlighted in yellow
Fig. 8Graphical summary and hypothesis relating major findings of this work and published data. The figure is not intended to give a comprehensive overview of the entire metabolism and stress responses in N. meningitidis but to illustrate pathways that link metabolism, protein sequence and gene expression differences of selected (virulence-associated) genes and the pathogenesis of IMD as described in the main text. Accordingly, genes and pathways that were highly expressed in MC58 in blood and/or that are strongly upregulated between saliva and blood in MC58 are depicted in red, and genes and pathways that are highly expressed in α522 or that are strongly upregulated between saliva and blood in α522 are depicted in green. Asterisks next to enzyme or protein names indicate that the corresponding proteins have a less than average sequence similarity (BSRP < 0.958) or are entirely missing in strain α522. Arrows with plus signs indicate (predominantly) activating regulatory interactions, and arrows with minus signs (predominantly) inhibitory regulatory interactions. For further details and abbreviations see main text. The literature cited in the figure is indicated by bracketed numerals next to the respective arrows: (1) Newcombe et al. (2005) [33], (2) Delany et al. (2006) [70], (3) Fantappie et al. (2009) [74], (4) Monaco et al. (2006) [87], (5) Huis in’t Veld et al. (2011) [72], (6) Tala et al. (2011) [86], (7) Takahashi et al. (2015) [124], (8) Gunesekere et al. [71], (9) Criss and Seifert (2012) [38], (10) Seib et al. (2006) [84], (11) Schmitt et al. (2009) [83], (12) Stevanin et al. (2007) [52], (13) Kobsar et al. (2011) [51], (14) Coureuil et al. (2014) [125], (15) Virji (2009) [49], (16) Hellerud et al. (2015) [48]